The Preclinical Tumor Analysis and Imaging (PTAI) Shared Resource is dedicated to facilitating in vivo studies of tumors by Cancer Center members. This Shared Resource serves to move research projects from the bench or from a patient's sample into an in vivo animal model context, thereby enhancing the translation of discoveries into useful knowledge for potential therapeutic applications. PTAI was formed by merging the pre-existing Molecular Assessment and Preclinical Studies (MAPS) shared resource with the Animal Imaging Shared Resource, so as to better integrate imaging into analyses of animal tumor models. The PTAI Shared Resource tests therapies involving small molecules, biologies, and/or radiation in a variety of tumor models and also helps translational investigators generate these models. This resource offers guidance and assistance for the design and performance of standardized or customized protocols for subcutaneous and orthotropic xenograft and syngenic mouse models. The PTAI Shared Resource uses ACUC approved protocols to perform preclinical studies, can follow established protocols, and will help investigators design custom protocols. New emphasis is placed on the noninvasive detection and measurement of tumor growth and spread using bioluminescence, PET or MRI. Staff members have considerable experience and serve as consultants and trainers as well as service providers. They also act as agents to coordinate services in other shared resources, providing a single point of contact for a PI to carry out an entire study that might include culture of cells, immunohistochemistry, flow cytometry, molecular analyses of tumors, and statistics. The PTAI provides laboratory services to clinicians, some of whom may not have appropriate laboratory facilities or staff, and initiates animal studies for laboratory scientists who have inadequate experience with in vivo models and otherwise depend solely on in vitro models. The advantages provided by in vivo preclinical studies include the development of whole animal model systems for 1) drug response predictions in human patients and analysis of mechanisms, 2) depicting the heterogeneity of human tumor cells, the complexity of which cannot be obtained within the confines of in vitro studies;3) mimicking the tumor microenvironment and 4) tracking the progression, spread and invasion of metastatic cancers. The services offered by PTAI are an integral part of the Cancer Center translational research initiatives.

Public Health Relevance

The PTAI provides the tools that link mouse models to human tissues, and is a critical facilitator of translational research. It enables basic scienfists to do animal experiments and clinical scientists to access lab techniques.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA044579-21
Application #
8231143
Study Section
Subcommittee G - Education (NCI)
Project Start
2012-02-01
Project End
2017-01-31
Budget Start
2012-06-05
Budget End
2013-01-31
Support Year
21
Fiscal Year
2012
Total Cost
$83,282
Indirect Cost
$30,460
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Borten, Michael A; Bajikar, Sameer S; Sasaki, Nobuo et al. (2018) Automated brightfield morphometry of 3D organoid populations by OrganoSeg. Sci Rep 8:5319
Olson, Kristine C; Kulling Larkin, Paige M; Signorelli, Rossana et al. (2018) Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes. Cytokine 111:551-562
Pfister, Katherine; Pipka, Justyna L; Chiang, Colby et al. (2018) Identification of Drivers of Aneuploidy in Breast Tumors. Cell Rep 23:2758-2769
Carhart, Miev Y; Schminkey, Donna L; Mitchell, Emma M et al. (2018) Barriers and Facilitators to Improving Virginia's HPV Vaccination Rate: A Stakeholder Analysis With Implications for Pediatric Nurses. J Pediatr Nurs 42:1-8
Hao, Yi; Bjerke, Glen A; Pietrzak, Karolina et al. (2018) TGF? signaling limits lineage plasticity in prostate cancer. PLoS Genet 14:e1007409
Obeid, Joseph M; Kunk, Paul R; Zaydfudim, Victor M et al. (2018) Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time? Cancer Immunol Immunother 67:161-174
Wallrabe, Horst; Svindrych, Zdenek; Alam, Shagufta R et al. (2018) Segmented cell analyses to measure redox states of autofluorescent NAD(P)H, FAD & Trp in cancer cells by FLIM. Sci Rep 8:79
Olmez, Inan; Love, Shawn; Xiao, Aizhen et al. (2018) Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro Oncol 20:192-202
Wang, T Tiffany; Yang, Jun; Zhang, Yong et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective ?-chain cytokines, decreases leukemic T-cell viability. Leukemia :
Yao, Nengliang; Zhu, Xi; Dow, Alan et al. (2018) An exploratory study of networks constructed using access data from an electronic health record. J Interprof Care :1-8

Showing the most recent 10 out of 539 publications